A Clinical Study To Evaluate the Safety and Efficacy of HABB-E-IRQ-UN-NISA in the Management Of NIQRIS (GOUT)

An Open Labelled Randomized Active Controlled Clinical Study to Evaluate the Safety and Efficacy of HABB-E-IRQ-UN-NISA in the Management of Niqris (Gout) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075131

Enrollment

Registered

2024-10-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

Intervention1: HABB-E-IRQ-UN-NISA: HABB-E-IRQ-UN-NISA 2.5 gm BD orally with water after meals Each patient is treated with unani formulation with total duration of 60 days Control Intervention1: Tab

Eligibility

Inclusion criteria

Inclusion criteria: Patient with clinical features of gout associated with increased serum uric acid levels i.e., In males more than 7.0mg/dL In females more than 6.0mg/dL

Exclusion criteria

Exclusion criteria: 1. Chronic tophaceous gout 2. Pregnant and Lactating females 3. Serious dysfunction of renal, cardiac, liver & pulmonary 4. Patient with neurological disorder 5. Uncontrolled diabetes

Design outcomes

Primary

Measure	Time frame
To reduce the serum uric acid levelsTimepoint: once in 2 weeks	—

Secondary

Measure	Time frame
To relieve joint pain joint tenderness joint swelling and restriction of joint movementsTimepoint: once in 2 weeks	—

Countries

India

Contacts

Public ContactDr Dhobi Athiya

Government Nizamia Tibbi College

drsakhussaini@gmail.com9704888561

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026